Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:52:23.058Z.
Calculation as of: 2026-10-06T16:52:23.058Z.
Quote observation: 2026-10-06T16:50:16.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 619c5482a9d59cec4bb20d2c4447c35828cdfaa1e6076b938dd954a9c5cde0ad
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$1.98B
EBITDA Yield
3.79%
TTM Avg
3.64%
3Y Avg
2.44%
5Y Avg
2.44%
Market Cap
$2.02B
EBITDA Yield
8.96%
TTM Avg
5.82%
3Y Avg
4.86%
5Y Avg
4.86%
Market Cap
$2.04B
EBITDA Yield
N/A
TTM Avg
4.83%
3Y Avg
4.83%
5Y Avg
4.83%
Market Cap
$1.91B
EBITDA Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | $1.98B | N/A | N/A | N/A | N/A |
| Inspire Medical Systems, Inc. (INSP)vs › | $1.98B | 3.79% | 3.64% | 2.44% | 2.44% |
| AxoGen, Inc. (AXGN)vs › | $1.96B | N/A | 0.87% | 0.82% | 0.82% |
| Aurinia Pharmaceuticals Inc. (AUPH)vs › | $2.02B | 8.96% | 5.82% | 4.86% | 4.86% |
| Progyny, Inc. (PGNY)vs › | $2.04B | 6.23% | 5.01% | 3.79% | 2.59% |
| BioCryst Pharmaceuticals, Inc. (BCRX)vs › | $2.04B | N/A | 4.83% | 4.83% | 4.83% |
| Establishment Labs Holdings Inc. (ESTA)vs › | $1.91B | N/A | N/A | N/A | N/A |
| Alvotech (ALVO)vs › | $2.05B | 2.40% | 3.21% | 2.55% | 2.55% |
| Fortrea Holdings Inc. (FTRE)vs › | $2.06B | 2.97% | 2.90% | 2.55% | 2.99% |
| Immunome, Inc. (IMNM)vs › | $1.90B | N/A | N/A | N/A | N/A |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
